Moore'S Compounding Levothyroxine Sodium mcg/Liothyronine Recall

Why it was recalled

Superpotent Drug and Subpotent Drug; potency failures obtained

Product description

Levothyroxine Sodium 135 mcg/Liothyronine 15 mcg SR capsules, 90 count bottles, Rx only, Moore's Pharmacy Compounding, Corpus Christi, TX

Lot numbers, UPCs & expiration codes

2016-08-22:37@28, exp 2/18/2017

Where it was sold

What to do if you have this product

Compare the lot number and expiration date on your package with the codes above.
Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
If you have symptoms you think are related, contact your doctor. In an emergency call 911.
Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number: D-0488-2017
Classification: Class II
Status: Terminated
Recall initiated: Sep 12, 2016
FDA report date: Mar 1, 2017
Quantity: 90 capsules
Recall type: Voluntary: Firm initiated
Recalling firm: MOORE'S COMPOUNDING PHARMACY

Original FDA data

Every field from FDA enforcement report D-0488-2017, exactly as published.

Show all FDA fields

City: Corpus Christi
State: TX
Status: Terminated
Country: United States
Event ID: 76235
Address: 5945 McArdle Rd Ste 101
Code information: 2016-08-22:37@28, exp 2/18/2017
Postal code: 78412-3491
Report date: Mar 1, 2017
Product type: Drugs
Recall number: D-0488-2017
Classification: Class II
Recalling firm: MOORE'S COMPOUNDING PHARMACY
Product quantity: 90 capsules
Termination date: May 17, 2017
Reason for recall: Superpotent Drug and Subpotent Drug; potency failures obtained
Voluntary / mandated: Voluntary: Firm initiated
Product description: Levothyroxine Sodium 135 mcg/Liothyronine 15 mcg SR capsules, 90 count bottles, Rx only, Moore's Pharmacy Compounding, Corpus Christi, TX
Distribution pattern: TX
Recall initiation date: Sep 12, 2016
Initial firm notification: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date: Feb 21, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0488-2017, published Mar 1, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: Oct 2, 2026. Content last changed: Oct 2, 2026.

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

Moore'S Compounding Pharmacy Levothyroxine Sodium 135 mcg/Liothyronine 15 Recall

Summary